Scott Bizily Sells 1,750 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,750 shares of the stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $25.74, for a total transaction of $45,045.00. Following the completion of the sale, the insider now directly owns 1,737 shares in the company, valued at approximately $44,710.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Scott Bizily also recently made the following trade(s):

• On Monday, April 1st, Scott Bizily sold 8,153 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $31.78, for a total transaction of $259,102.34.
• On Wednesday, March 27th, Scott Bizily sold 5,833 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $35.04, for a total transaction of $204,388.32.
• On Monday, March 18th, Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $31.27, for a total transaction of $54,722.50.
• On Tuesday, February 27th, Scott Bizily sold 1,909 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $30.00, for a total transaction of $57,270.00.
• On Friday, February 16th, Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $27.67, for a total transaction of $48,422.50.
• On Thursday, February 8th, Scott Bizily sold 6,244 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $27.50, for a total transaction of $171,710.00.

4D Molecular Therapeutics Stock Performance

NASDAQ:FDMT opened at $25.25 on Friday. 4D Molecular Therapeutics, Inc. has a fifty-two week low of $9.44 and a fifty-two week high of $36.25. The stock has a market capitalization of $1.29 billion, a P/E ratio of -9.49 and a beta of 2.87. The company’s 50-day simple moving average is $28.90 and its 200-day simple moving average is $20.22.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings results on Thursday, February 29th. The company reported ($0.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.09). 4D Molecular Therapeutics had a negative net margin of 436.30% and a negative return on equity of 34.14%. The firm had revenue of ($0.02) million during the quarter, compared to the consensus estimate of $4.67 million. On average, research analysts forecast that 4D Molecular Therapeutics, Inc. will post -3.03 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on FDMT. Jefferies Financial Group upped their price target on shares of 4D Molecular Therapeutics from $30.00 to $58.00 and gave the stock a “buy” rating in a report on Monday, April 1st. HC Wainwright restated a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Friday, March 1st. The Goldman Sachs Group reiterated a “buy” rating and set a $81.00 target price on shares of 4D Molecular Therapeutics in a report on Wednesday, February 7th. Barclays initiated coverage on shares of 4D Molecular Therapeutics in a report on Monday, April 15th. They set an “overweight” rating on the stock. Finally, Royal Bank of Canada increased their target price on shares of 4D Molecular Therapeutics from $35.00 to $40.00 and gave the stock an “outperform” rating in a report on Monday, April 15th. Ten equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, 4D Molecular Therapeutics has a consensus rating of “Buy” and an average price target of $44.22.

Institutional Trading of 4D Molecular Therapeutics

Institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp boosted its holdings in shares of 4D Molecular Therapeutics by 16.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 135,711 shares of the company’s stock valued at $1,728,000 after buying an additional 19,434 shares in the last quarter. Trexquant Investment LP purchased a new position in shares of 4D Molecular Therapeutics in the 3rd quarter valued at approximately $566,000. Aigen Investment Management LP purchased a new position in shares of 4D Molecular Therapeutics in the 3rd quarter valued at approximately $216,000. Wellington Management Group LLP raised its position in shares of 4D Molecular Therapeutics by 2.2% in the 3rd quarter. Wellington Management Group LLP now owns 172,722 shares of the company’s stock valued at $2,199,000 after purchasing an additional 3,638 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of 4D Molecular Therapeutics by 359.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,951 shares of the company’s stock valued at $100,000 after purchasing an additional 3,873 shares during the last quarter. 99.27% of the stock is currently owned by institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.